BioXcel Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Good afternoon. I'm Carter Gould, senior biopharma analyst here at Barclays. I'm delighted to welcome BioXcel to the Barclays virtual Global Healthcare Conference. BioXcel has been one of those stories where the company just sort of kept their head down in the past 2 years, continue to execute, and it's good to see their lead asset, BXCL501, come into greater focus from investors over the past couple of months.
We're joined today by the company's CEO and Founder, Vimal Mehta. He will provide the presentation today. Vimal?
Thank you, Carter. Good afternoon. And thank you for joining us today. As a reminder, I will be making forward-looking statements regarding our clinical programs and business outlook in addition to regulatory product development. That's on Slide #2.
Coming back to Slide #3. For those who are following the slide, it's a virtual presentation, so I will do my best to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |